Caribou Biosciences Inc Total Assets
Caribou Biosciences Inc total assets. Based on the latest financial reports, Caribou Biosciences Inc (CRBU) holds total assets worth $142.77 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Caribou Biosciences Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Caribou Biosciences Inc (2019–2025)
Total assets of Caribou Biosciences Inc from 2019 to 2025. This chart illustrates how Caribou Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Caribou Biosciences Inc for real-time trading data and today's change.
Caribou Biosciences Inc - Asset Composition Analysis
Caribou Biosciences Inc Total Assets Breakdown (December 2025)
Caribou Biosciences Inc total assets breakdown as of December 2025. Caribou Biosciences Inc's total assets of $142.77 Million consist of 82.8% current assets and 17.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.1% |
| Accounts Receivable | $2.98 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CRBU working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Caribou Biosciences Inc's current assets represent 82.8% of total assets in 2025, a decrease from 92.1% in 2019.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2025, down from 66.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Caribou Biosciences Inc Competitors by Total Assets
Key competitors of Caribou Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Caribou Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.49 | 6.66 | 17.17 |
| Quick Ratio | 6.49 | 6.66 | 16.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $98.62 Million | $163.62 Million | $422.89 Million |
Caribou Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Caribou Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.42 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | -44.0% |
| Total Assets | $175.37 Million |
| Market Capitalization | $47.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Caribou Biosciences Inc's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Caribou Biosciences Inc's assets decreased by 44.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Caribou Biosciences Inc (2019–2025)
The table below shows the annual total assets of Caribou Biosciences Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $175.37 Million | -44.03% |
| 2024-12-31 | $313.31 Million | -27.51% |
| 2023-12-31 | $432.21 Million | +15.64% |
| 2022-12-31 | $373.76 Million | -15.51% |
| 2021-12-31 | $442.36 Million | +1127.20% |
| 2020-12-31 | $36.05 Million | -41.80% |
| 2019-12-31 | $61.93 Million | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD… Read more